# Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 4)

> **NCT03400956** · PHASE3 · TERMINATED · sponsor: **Bayer** · enrollment: 103 (actual)

## Conditions studied

- Uterine Fibroids

## Interventions

- **DRUG:** Vilaprisan (BAY1002670)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03400956
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-01-24
- **Primary completion:** 2019-03-23
- **Final completion:** 2021-06-30
- **Target enrollment:** 103 (ACTUAL)
- **Why stopped:** Due to a change in the development program, the study was closed prematurely.
- **Last updated:** 2022-06-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03400956

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03400956, "Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 4)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03400956. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*